COVID-19, Vaccination and Longer-term health consequences of COVID-19 in Luxembourg 

Despite the broad availability of effective vaccines against COVID-19 in advanced economies, such as in Luxembourg, societies continue to face multifaceted challenges emanating from the COVID-19 pandemic. A major question presently concerns the longer-term effects of COVID-19, especially concerning Long COVID in susceptible populations such as children. Furthermore, the vaccines' effectiveness in light of emerging variants, waning immunity and hesitancy to get vaccinated, contribute altogether toward uncertainty as to how best to deal with the COVID-19 crisis in the months and years to come. Through the leveraging of the extensive interdisciplinary expertise represented by the different public research institutions in Luxembourg, the CoVaLux research programme tackles the most pertinent and urgent research questions emanating from the COVID-19 pandemic in a flexible manner. Its two main research axes focus on the symptomatology, prevalence and socioeconomic factors of long COVID and on the short- to mid-term impact of vaccination, respectively. By providing the necessary data and empirical evidence, CoVaLux contributes towards enhanced prevention, diagnosis, prognosis, support and treatment of long COVID as well as the optimisation of the vaccination campaign in Luxembourg. Furthermore, through its population-based approach as well as the extensive data available on the Luxembourg population, the results of this nationwide test case will be of immediate international relevance as well. Finally, by contributing factual analyses and bases, CoVaLux directly supports stakeholders in evidence-based decision making with immediate, tangible impacts on society.